<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>19914780</Do_id>
  <Journal>Cancer treatment reviews</Journal>
  <Doc_title>Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.</Doc_title>
  <Doc_abstract>Resistance to tyrosine-kinase inhibitors remains an open issue in the treatment of patients with gastrointestinal stromal tumors. The complex biology of disease in the multi-resistant setting has led a progressively growing urgency and interest in development combined or integrated therapies. This mini-review outlines the rationale for developing new combined therapeutic approaches, and describes the state of the art of the various potential strategies and the promising research perspectives.</Doc_abstract>
  <Doc_ChemicalList>Benzamides;Indoles;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Pyrroles;Imatinib Mesylate;sunitinib</Doc_ChemicalList>
  <Doc_meshdescriptors>Antineoplastic Combined Chemotherapy Protocols;Benzamides;Combined Modality Therapy;Gastrointestinal Stromal Tumors;Humans;Imatinib Mesylate;Indoles;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Pyrroles</Doc_meshdescriptors>
  <Doc_meshqualifiers>therapeutic use;drug therapy;genetics;therapy;therapeutic use;therapeutic use;therapeutic use;therapeutic use;therapeutic use</Doc_meshqualifiers>
</Document>
